Erika P. Hamilton, MD

Erika P. Hamilton, MD, is the director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute.

Articles

Looking to the Future: Emerging Therapeutic Approaches in HER2+ Breast Cancer

June 4th 2025

Panelists discuss how emerging developments in HER2-positive (HER2+) breast cancer treatment, including novel antibody-drug conjugates, bispecific antibodies, and cytotoxic-sparing regimens for hormone receptor+ (HR+)/HER2+ disease, are creating exciting new options for patients.

Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer

June 2nd 2025

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Clinical Insights Into Managing Heavily Pretreated HER2+ Metastatic Breast Cancer

May 28th 2025

Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.

Balancing Efficacy and Tolerability: Expert Insights Into Tucatinib Triplet Therapy for HER2+ Breast Cancer

May 28th 2025

Panelists discuss how they manage adverse effects of tucatinib-based therapy, particularly focusing on diarrhea and palmar-plantar erythrodysesthesia from capecitabine, with practical dosing strategies to improve tolerability.

Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05

May 21st 2025

Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to potentially prevent brain metastases.

Navigating Third-Line Treatment Options in HER2+ Breast Cancer: ADC or TKI

May 21st 2025

Panelists discuss how National Comprehensive Cancer Network (NCCN) guidelines inform third-line treatment options for HER2-positive (HER2+) metastatic breast cancer, with particular focus on the HER2CLIMB regimen (tucatinib, capecitabine, and trastuzumab) for patients with brain metastases.

Clinical Insights on the Next Treatment Approach for Metastatic HER2+ Breast Cancer with Brain Metastasis

May 14th 2025

Panelists discuss how they would approach multiple brain metastases at initial metastatic diagnosis, debating the use of stereotactic radiosurgery vs systemic therapy with agents that cross the blood-brain barrier.

Forty-Seven-Year-Old Woman With Recurrent HER2+ Breast Cancer and Brain Metastases

May 14th 2025

Panelists discuss how they approach the case of a 47-year-old marketing executive with initially low-risk HER2-positive (HER2+) breast cancer who developed brain, liver, lung, and bone metastases shortly after completing adjuvant therapy.

Managing Brain Metastases in HER2+ Breast Cancer: Second-Line Treatment Decisions

May 7th 2025

Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtecan’s (T-DXd) efficacy in patients with brain metastases.

Expert Perspectives on Navigating Treatment-Related Adverse Events With T-DXd

May 7th 2025

Panelists discuss how they manage adverse effects of trastuzumab deruxtecan (T-DXd), particularly focusing on nausea, fatigue, and the critical monitoring needed for interstitial lung disease (ILD), with recommendations for prophylactic antiemetics and frequent imaging.

Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case

April 30th 2025

Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and the impressive results from the PATINA trial adding CDK4/6 inhibitors to maintenance therapy.

Clinical Scenario I: 52-year-old Woman With Recurrent Metastatic HER2+ Breast Cancer

April 30th 2025

Panelists discuss how a 52-year-old elementary school teacher diagnosed with HER2-positive (HER2+) breast cancer achieved pathologic complete response with neoadjuvant therapy but experienced metastasis 18 months after completing treatment, requiring first-line metastatic therapy.

Dr Hamilton on Treatment Selection After Progression on Frontline CDK4/6 Inhibition in HR+ Breast Cancer

April 10th 2025

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

August 22nd 2024

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer Paradigm

August 7th 2024

Erika P. Hamilton, MD, discusses the efficacy of trastuzumab deruxtecan in patients with HER2-low breast cancer.

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 16th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

July 16th 2024

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 9th 2024

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.

Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291

July 9th 2024

Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 3rd 2024

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.